CHMP

YESINTEK recommended for approval to treat psoriasis, psoriatic arthritis, and Crohn’s disease in adults and children

YESAFILI is intended for the treatment of neovascular age-related macular degeneration, visual impairment due to macular oedema…

While many patients will benefit from available TKI therapies, a significant proportion may experience intolerance or resistance…

Valneva said the EMA Committee for Medicinal Products for Human Use (CHMP) had a fresh list of questions, including requests for…

The recommendation is based on pivotal data from the phase-III Polarix study

Valneva has received a list of questions on its VLA2001 vaccine from the Committee for Medicinal Products for Human Use (CHMP) and…

Approval based on results from four phase-III studies in motre than 5,500 patients

Actemra/RoActemra reduced the risk of death in patients with severe COVID-19, as evidenced by a review of four phase-III studies.…

The decision follows one day after the positive opinion by the EMA Committee for CHMP, reflecting the EMA and the European…

Recommendation is based on the phase-III Ascent study showing that Sacituzumab Govitecan significantly improved the overall…